Hot Investor Mandate: USA & Asia-Based Firm Seeks Early-Stage Investment Opportunities in Therapeutics, Molecular Diagnostics, Digital Health

20 Feb

An early stage investment firm with offices in USA and Asia focuses on facilitating the development and commercialization of high-potential, high-impact life science innovations arising from the U.S., Canada, South Korea, China and other markets that represent a significant source of opportunities for outsized value creation. The firm makes initial seed investments of US$100K – 1M and can bring in strategic capital from Asia to facilitate global development and market entry. The firm expects to make 2-3 new investments in the coming year.

Within life sciences, the firm is mostly interested in therapeutics, molecular diagnostics and digital health. The firm takes an opportunistic approach when it comes to disease areas and targets early stage innovation on the cusp of preclinical proof-of-concept or validation.

The firm is looking for capable teams developing innovative technologies. The firm works actively with entrepreneurs to devise and implement development and commercialization strategies, help assemble management personnel, and secure additional capital. For more mature opportunities, the firm will add value by using its fundraising, monetization, business development and licensing expertise to help secure investments and partnerships that will fund and expedite eventual commercialization.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: